Su Jin Park

Su Jin Park

Auto-generated profile, based on publicly available information

Su Jin Park

BioMedical Research Institute, Pusan National University Hospital, Busan, Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2019 in Gut and Liver
Verified
Journal Article
Open access
PDF file
MLMoon Won Lee
Moon Won Lee
Gwang Ha KimGwang Ha Kim
Gwang Ha Kim
HJHye Kyung Jeon
Hye Kyung Jeon
SPSu Jin Park
Su Jin Park
Moon Won Lee, Gwang Ha Kim, Hye Kyung Jeon, and Su Jin Park. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl18484

1 January 2022 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
DKDong Hwahn Kahng
Dong Hwahn Kahng
Gwang Ha KimGwang Ha Kim
Gwang Ha Kim
SPSu Jin Park
Su Jin Park
SKSora Kim
Sora Kim
MLMoon Won Lee
Moon Won Lee
HIHoseok I
Hoseok I
Kahng DH, et al. J Korean Med Sci. 2022 Jun;37(24):e197. https://doi.org/10.3346/jkms.2022.37.e197

15 July 2021 in Gut and Liver
Verified
Journal Article
Open access
PDF file
HLHyun Jung Lee
Hyun Jung Lee
Gwang Ha KimGwang Ha Kim
Gwang Ha Kim
SPSu Jin Park
Su Jin Park
CKChae Hwa Kwon
Chae Hwa Kwon
MLMoon Won Lee
Moon Won Lee
HIHoseok I
Hoseok I
Hyun Jung Lee, Gwang Ha Kim, Su Jin Park, Chae Hwa Kwon, Moon Won Lee, Bong Eun Lee, Dong Hoon Baek, and Hoseok I. Gut and Liver 2021;15:553-61. https://doi.org/10.5009/gnl20194

29 June 2026 in Gut and Liver
Verified
Journal Article
Open access
DJDong Chan Joo
Dong Chan Joo
SPSu Jin Park
Su Jin Park
Gwang Ha KimGwang Ha Kim
Gwang Ha Kim
MLMoon Won Lee
Moon Won Lee
BLBong Eun Lee
Bong Eun Lee
Clinically useful noninvasive biomarkers for gastric cancer remain limited. Extracellular vesicles (EVs) carry a molecular cargo reflective of their cells of origin and have emerged as promising candidates for blood-based cancer biomarkers. We aimed to identify EV-associated protein biomarkers for gastric cancer via a proteomic approach. Proteomic profiling of EVs was performed using one normal gastric cell line (Hs738st/int) and two gastric cancer cell lines (AGS and NCI-N87). Selected proteins were validated in blood-derived EVs isolated from plasma samples of 10 healthy controls and 36 patients with gastric cancer. Proteomic analysis identified 224 differentially expressed proteins whose expression was consistently altered in gastric cancer cell line-derived EVs. Among these, vitronectin (VTN) and laminin subunit alpha-3 (LAMA3) were selected based on their consistent upregulation. EV-associated LAMA3 levels were significantly higher in patients with gastric cancer than in healthy controls (p=0.003), with significant elevations observed from stage II onward (p=0.041, p=0.017, and p=0.004 for stages II, III, and IV, respectively). EV-associated VTN levels were not significantly different overall (p=0.089); however, stage-specific analysis demonstrated significant increases in VTN levels in patients with stage III (p=0.036) and stage IV (p=0.005) gastric cancer. Both EV-associated VTN and LAMA3 levels showed significant positive correlations with the cancer stage (ρ=0.564 and ρ=0.611, respectively; both p<0.001). The levels of EV-associated VTN and LAMA3 appear to be more closely associated with disease progression than with early-stage detection of gastric cancer. These findings suggest that EV-based proteomic biomarkers may have clinical utility for monitoring tumor progression in patients with clinically advanced gastric cancer.